NCT02222779

Brief Summary

In this trial, concentrations of transition metals of interest are quantified in surplus cerebrospinal fluid (CSF) and blood serum samples. Quantification of the transition metals will be performed by inductively coupled plasma mass spectrometry (ICP-MS). The treating physicians as well as the patients will not be informed about the results of drug concentrations.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3,000

participants targeted

Target at P75+ for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 20, 2014

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 21, 2014

Completed
11 days until next milestone

Study Start

First participant enrolled

September 1, 2014

Completed
4.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2019

Completed
Last Updated

August 21, 2014

Status Verified

August 1, 2014

Enrollment Period

4.9 years

First QC Date

August 20, 2014

Last Update Submit

August 20, 2014

Conditions

Neurodegenerative DiseasesInfections

Outcome Measures

Primary Outcomes (1)

  • Transition metal concentration

    5 years

Study Arms (4)

Patients with Parkinson´s Disease

Patient´s with Alzheimer´s Disease

Patients with Multiple Sclerosis

Patients with any other neurodegenerative diseases

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

neurodegenerative diseases infections

You may qualify if:

  • The trial will include any patient (with various diseases, especially neurodegenerative diseases) who received a lumbar puncture.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Pharmacology

Cologne, North Rhine-Westphalia, 50829, Germany

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Remaining portions of samples collected for diagnostic or therapeutic reasons (paired CSF and blood serum samples). No lumbar puncture will be done specifically for this protocol.

MeSH Terms

Conditions

Neurodegenerative DiseasesInfections

Condition Hierarchy (Ancestors)

Nervous System Diseases

Central Study Contacts

Uwe Fuhr, Professor

CONTACT

0049221478uwe.fuhr@uk-koeln.de

Study Design

Study Type
observational
Observational Model
ECOLOGIC OR COMMUNITY
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Quantification of Transition Metals in Patients at the Cologne University Hospital

Study Record Dates

First Submitted

August 20, 2014

First Posted

August 21, 2014

Study Start

September 1, 2014

Primary Completion

August 1, 2019

Last Updated

August 21, 2014

Record last verified: 2014-08

Locations

DE(1)